CVS Health Corp (CVS) concluded trading on Wednesday at a closing price of $68.07, with 5.68 million shares of worth about $386.71 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 8.25% during that period and on April 03, 2025 the price saw a gain of about 0.13%. Currently the company’s common shares owned by public are about 1.26B shares, out of which, 1.26B shares are available for trading.
Stock saw a price change of 1.29% in past 5 days and over the past one month there was a price change of 6.01%. Year-to-date (YTD), CVS shares are showing a performance of 51.64% which decreased to -14.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $43.56 but also hit the highest price of $75.27 during that period. The average intraday trading volume for CVS Health Corp shares is 11.04 million. The stock is currently trading 1.93% above its 20-day simple moving average (SMA20), while that difference is up 8.46% for SMA50 and it goes to 16.80% higher than SMA200.
CVS Health Corp (NYSE: CVS) currently have 1.26B outstanding shares and institutions hold larger chunk of about 84.26% of that.
The stock has a current market capitalization of $85.82B and its 3Y-monthly beta is at 0.60. PE ratio of stock for trailing 12 months is 18.61, while it has posted earnings per share of $3.66 in the same period. Its PEG reads 1.37 and has Quick Ratio of 0.60 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CVS, volatility over the week remained 1.87% while standing at 2.50% over the month.
Stock’s fiscal year EPS is expected to rise by 8.91% while it is estimated to increase by 16.38% in next year. EPS is likely to grow at an annualized rate of 13.56% for next 5-years, compared to annual growth of -6.37% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 13, 2025 offering an Outperform rating for the stock and assigned a target price range of between $55 and $75 to it. On January 30, 2025, Edward Jones Upgrade their recommendations, while on December 03, 2024, Deutsche Bank Upgrade their ratings for the stock with a price target of $66. Stock get an Overweight rating from Wells Fargo on November 18, 2024.
